The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of angina and thrombosis are listed in the xience skypoint, everolimus eluting coronary stent system (eecss), electronic instructions for use (eifu) as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined; however, the reported treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the procedure was to treat a heavily calcified, 100% stenosed lesion in the left anterior descending (lad) artery.One-hour post deployment of a 3.5x28mm xience skypoint drug eluting stent (des), the patient was on the recovery floor when he experienced chest pain.The patient was taken to the cath lab and imaging was performed showing a thrombosis at the implanted stent.A device was used to aspirate the in-stent thrombosis.When the device was removed from the anatomy, it was noted that it did not remove the clot but pushed it distally.Subsequently, the patient was fine and moved back to the recovery floor with no further intervention required.There was no adverse patient sequela and no reported clinically significant delay in the procedure or therapy.No additional information was provided.
|